Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00191139 · ClinicalTrials.gov registry record · Phase 2
Gemcitabine or Gemcitabine Plus Docetaxel After Cisplatin, Etoposide and Radiation in Non Small Cell Lung Cancer (NSCLC)
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 64
- Enrollment target
NCT00191139 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 64 participants.
The verdict
NCT00191139, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 64 participants
- Enrollment target
Study Summary
To assess the 2 year survival of patients with Stage III unresectable non-small cell lung cancer receiving consolidation gemcitabine or gemcitabine plus docetaxel following concurrent chemotherapy and radiation.
Interventions
- DRUG cisplatin
- DRUG docetaxel
- DRUG gemcitabine
- DRUG etoposide
- RADIATION radiation therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2003-03 |
| Est. Completion | 2009-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00191139
The ClinicalTrials.gov registry entry for NCT00191139 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cisplatin is the first listed.
NCT00191139 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00191139 about?
NCT00191139 is a clinical study titled "Gemcitabine or Gemcitabine Plus Docetaxel After Cisplatin, Etoposide and Radiation in Non Small Cell Lung Cancer (NSCLC)". To assess the 2 year survival of patients with Stage III unresectable non-small cell lung cancer receiving consolidation gemcitabine or gemcitabine plus docetaxel following concurrent chemotherapy and radiation.
What is the current status of trial NCT00191139?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 64 participants. The study started on 2003-03. Estimated completion is 2009-02.
What interventions are being tested in trial NCT00191139?
The interventions under investigation include: cisplatin (DRUG), docetaxel (DRUG), gemcitabine (DRUG), etoposide (DRUG), radiation therapy (RADIATION).
Who is sponsoring clinical trial NCT00191139?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.